ArticleFrontiers in neurology
Quantitative evaluation of iron chelator effects on central motor and sensory tracts in superficial siderosis.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Superficial siderosis (SS) is a rare neurodegenerative disease characterized by hemosiderin deposition in the central nervous system, leading to progressive neuronal degeneration. Although myelopathy is a main clinical manifestation in SS, objective biomarkers for monitoring disease progression and treatment remain unclarified. We assessed electrophysiology of central motor and sensory conduction in patients with SS before and after iron chelator administration. Methods: In this controlled trial, we evaluated 12 patients with SS (mean follow-up: 33.6 months [range: 18.9-36.1]), who underwent dural repair, and 9 with multiple sclerosis as controls. Transcranial magnetic stimulation (TMS) and somatosensory evoked potentials (SEPs) were used to assess motor and sensory conduction, respectively. Eight patients with SS received oral iron chelator deferiprone (1,500 mg/day), whereas four underwent surgical repair without iron chelation. Primary outcomes were changes in central motor conduction time (CMCT), motor evoked potential (MEP) amplitude, and central sensory conduction time (CCT). Results: At baseline, 92 and 100% of patients with SS exhibited prolonged CMCT and CCT, respectively. Prolonged conduction in patients with SS was less severe than in those with multiple sclerosis (MS). Whereas MEP amplitude and the amplitude ratio of MEP to CMAP were relatively preserved in patients with SS. After 36-month iron chelator administration, statistically significant improvement of central motor conduction time was gained in patients with SS. Conclusion: TMS and SEP are sensitive tools for evaluating central conduction impairment in SS. The conduction abnormality, likely caused by a different pathomechanism from that in MS, is partially recoverable by iron chelator administration. CMCT improvement demonstrates partial reversibility of impaired motor pathway and supports the therapeutic potential of iron chelator therapy in SS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.